SCHEMBL1018889

SCHEMBL1018889

CN(c1ccc2c(n1)CCN(CC(=O)N1CCN(C3CCC3)CC1)C2)C1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.41
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 5/20 0.39
TSHR P16473 2/20 0.38
KMT2A Q03164 1/20 0.38
ALOX15 P16050 1/20 0.37
HRH3 Q9Y5N1 5/20 0.36
KCNH2 Q12809 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
USP2 O75604 1/20 0.36
UBE2N P61088 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD11B1 P28845 1/20 0.36
MAPK1 P28482 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1070174 0.91 PARP1 (0.39) PARP1ALDH1A1KDM4ETSHRKMT2A
SCHEMBL1016464 0.88 PARP1 (0.37) PARP1ALDH1A1KDM4ETSHRKMT2A
SCHEMBL1018061 0.86 PARP1 (0.36) PARP1ALDH1A1KDM4ETSHRKMT2A
SCHEMBL1603356 0.85 PARP1 (0.35) PARP1ALDH1A1KDM4ETSHRKMT2A
SCHEMBL1018243 0.84 ADRA1A (0.41) PARP1ALDH1A1KDM4ETSHRKMT2A
SCHEMBL14420825 0.83 PARP1 (0.34) PARP1ALDH1A1KDM4ETSHRKMT2A
SCHEMBL1017297 0.82 HRH3 (0.42) PARP1ALDH1A1KDM4ETSHRKMT2A
SCHEMBL1016304 0.81 HRH3 (0.43) PARP1ALDH1A1KDM4EHRH3KCNH2
SCHEMBL1603363 0.81 ALDH1A1 (0.40) PARP1ALDH1A1KDM4ETSHRKMT2A
SCHEMBL1015782 0.81 HRH3 (0.40) PARP1ALDH1A1KDM4ETSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
EP-1998620-B1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORP (US) 2011-01-12 EP disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues HRH3, HRH4, HRH1 PARP1 3633/4885ALDH1A1 1229/4885KDM4E 2634/4885
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 PARP1 3633/4885ALDH1A1 1229/4885KDM4E 2634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.